Bos JM - Search Results

1

HIV post-exposure prophylaxis: enhancing its pharmaco-economic profile by discriminate prescribing.

Postma MJ, Bos JM, de Jong-van den Berg LT, Tramarin A, van Bergen JE. Postma MJ, et al. Among authors: bos jm. AIDS. 2002 May 24;16(8):1177-9. doi: 10.1097/00002030-200205240-00012. AIDS. 2002. PMID: 12004277 No abstract available.

2

Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam.

Bos JM, Fennema JS, Postma MJ. Bos JM, et al. AIDS. 2001 Oct 19;15(15):2031-6. doi: 10.1097/00002030-200110190-00017. AIDS. 2001. PMID: 11600833

3

The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa.

Bos JM, Postma MJ. Bos JM, et al. Pharmacoeconomics. 2001;19(9):937-46. doi: 10.2165/00019053-200119090-00005. Pharmacoeconomics. 2001. PMID: 11700780 Review.

4

The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life.

Hubben GA, Bishai D, Pechlivanoglou P, Cattelan AM, Grisetti R, Facchin C, Compostella FA, Bos JM, Postma MJ, Tramarin A. Hubben GA, et al. Among authors: bos jm. AIDS Care. 2008 Apr;20(4):449-55. doi: 10.1080/09540120701867107. AIDS Care. 2008. PMID: 18449822

5

Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands.

Boersma C, Klok RM, Bos JM, Naunton M, van den Berg PB, de Jong-van den Berg LT, Postma MJ. Boersma C, et al. Among authors: bos jm. Appl Health Econ Health Policy. 2005;4(3):191-6. doi: 10.2165/00148365-200504030-00008. Appl Health Econ Health Policy. 2005. PMID: 16309337

6

The use of modeling in the economic evaluation of vaccines.

Bos JM, Alphen Lv, Postma MJ. Bos JM, et al. Expert Rev Pharmacoecon Outcomes Res. 2002 Oct;2(5):443-55. doi: 10.1586/14737167.2.5.443. Expert Rev Pharmacoecon Outcomes Res. 2002. PMID: 19807468

7

Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

Bos JM, Rümke HC, Welte R, Spanjaard L, van Alphen L, Postma MJ. Bos JM, et al. Pharmacoeconomics. 2006;24(2):141-53. doi: 10.2165/00019053-200624020-00004. Pharmacoeconomics. 2006. PMID: 16460135

8

Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands).

Postma MJ, Bos JM, Beutels P, Schilthuis H, van den Hoek JA. Postma MJ, et al. Among authors: bos jm. Vaccine. 2004 May 7;22(15-16):1862-7. doi: 10.1016/j.vaccine.2003.11.012. Vaccine. 2004. PMID: 15121296

9

Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands.

Bos JM, Rümke H, Welte R, Postma MJ. Bos JM, et al. Clin Ther. 2003 Oct;25(10):2614-30. doi: 10.1016/s0149-2918(03)80322-3. Clin Ther. 2003. PMID: 14667962

10

Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness?

Bos JM, Postma MJ. Bos JM, et al. Expert Rev Pharmacoecon Outcomes Res. 2004 Jun;4(3):247-50. doi: 10.1586/14737167.4.3.247. Expert Rev Pharmacoecon Outcomes Res. 2004. PMID: 19807306 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

227 results

Search Page

Filters